NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4106-4112

  Rosenzweig, Holly L ^a,b   Galster, Kellen ^a   Vance, Emily E ^a   Ensign Lewis, Joe ^a   Nunez, Gabriel ^c   Davey, Michael P ^a,b   Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR; CARD15 PROTEIN, MOUSE; CARD4 PROTEIN, MOUSE; CYTOKINE; MYD88 PROTEIN, MOUSE; TLR2 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HISTOPATHOLOGY; KNOCKOUT MOUSE; LEUKOCYTE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; UVEITIS; ANIMAL; AQUEOUS HUMOR; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DISEASE PREDISPOSITION; DRUG POTENTIATION; EYE; INNATE IMMUNITY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; VITREOUS BODY;

ANIMALS; AQUEOUS HUMOR; CYTOKINES; DISEASE SUSCEPTIBILITY; EYE; IMMUNITY, INNATE; INTRAVITREAL INJECTIONS; LEUKOCYTES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; UVEITIS; VITREOUS BODY;

EID: 80051665832     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6263     Document Type: Article

References (37)

1. Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol. 2006;90:103-108.
2. McCormack WJ, Parker AE, O'Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther. 2009;11:243-250.
3. Chen G, Shaw MH, Kim YG, Nunez G. Nod-like receptors: role in innate immunity and inflammatory disease. Ann Rev Pathol. 2009;4:365-398.
4. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19-20.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
6. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
7. Girardin SE, Travassos LH, Herve M, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem. 2003;278:41702-41708.
8. Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4:702-707.
9. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509-5512.
10. Shaw MH, Reimer T, Kim YG, Nunez G. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol. 2008;20:377-382.
11. Rosenzweig HL, Martin TM, Jann MM, et al. NOD2, the gene responsible for familial granulomatous uveitis, is essential in a mouse model of muramyl dipeptide-induced uveitis. Invest Ophthalmol Vis Sci. 2008;49:1518-1524.
12. Rosenzweig HL, Kawaguchi T, Martin TM, Planck SR, Davey MP, Rosenbaum JT. Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. Invest Ophthalmol Vis Sci. 2009;50:1739-1745.
13. Rosenzweig HL, Martin TM, Planck SR, et al. Activation of NOD2 in vivo induces IL-1 beta production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling. J Leukoc Biol. 2008;84:529-536.
14. Fritz JH, Girardin SE, Fitting C, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1-and NOD2-activating agonists. Eur J Immunol. 2005;35: 2459-2470.
15. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734.
16. van Heel DA, Ghosh S, Butler M, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol. 2005;35:2471-2476.
17. Uehara A, Yang S, Fujimoto Y, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with a chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2-and NOD1-dependent manner, respectively, in human monocyte cells in culture. Cell Microbiol. 2005;7:53-61.
18. Uehara A, Takada H. Synergism between TLRs and Nod1/2 in oral epithelial cells. J Dent Res. 2008;87:682-686.
19. Shikama Y, Kuroishi T, Nagai Y, et al. Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macropahges to produce pro-IL-1B and by down-regulation of suppressor of cytokine signaling 1 (SOCS1). Innate Immun. 2011;17(1):3-15.
20. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity. 2006;25:473-485.
21. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
22. Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008;118:545-559.
23. Rosenzweig H, Galster K, Planck S, Rosenbaum J. NOD1 is expressed in the eye and functionally contributes to IL-1{beta} dependent ocular inflammation in mice. Invest Ophthalmol. 2009;50:1746-1753.
24. Netea MG, Ferwerda G, de Jong DJ, Girardin SE, Kullberg BJ, van der Meer JW. NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-offunction phenotype. Neth J Med. 2005;63:305-308.
25. Van Heel DA, Hunt KA, King E, et al. Detection of muramyl dipeptide-sensing pathway defects in patients with Crohn's disease. Inflam Bowel Dis. 2006;12:598-605.
26. Takada H, Uehara A. Enhancement of TLR-mediate innate immune responses by peptidoglycans through NOD signaling. Curr Pharm Des. 2006;12:4163-4172.
27. Williams KL, Lich JD, Duncan JA, et al. The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem. 2005;280:39914-39924.
28. Conti BJ, Davis BK, Zhang J, O'Connor WJ, Williams KL, Ting JP. CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. J Biol Chem. 2005;280: 18375-18385.
29. Bruey JM, Bruey-Sedano N, Newman R, Chandler S, Stehlik C, Reed JC. PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages. J Biol Chem. 2004;279:51897-51907.
30. Yang Z, Fuss IJ, Watanabe T, et al. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology. 2007;133:1510-1521.
31. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:1069-1079.
32. Negishi H, Ohba Y, Yanai H, et al. Negative regulation of Toll-likereceptor signaling IRF-4. Proc Natl Acad Sci USA. 2005;102: 15989-15994.
33. Richardson WM, Sodhi CP, Russo A, et al. Nucleotide-binding oligomerization domain-2 inhibits Toll like receptor-4 signaling in the intestinal epithelium. Gastroenterology. 2010;139(3):904-17.
34. Rosenzweig HL, Jann MJ, Vance EE, Planck SR, Rosenbaum JT, Davey MP. Nucleotide-binding oligomerization domain 2 and Tolllike receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum. 2010;62:1051-1059.
35. Chauhan VS, Marriott I. Differential roles for NOD2 in osteoblast inflammatory immune responses to bacterial pathogens of bone tissue. J Med Microbiol. 2010;59:755-762.
36. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010;16:228-231.
37. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, et al. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc Natl Acad Sci USA. 2008;105:9017-9022.